论文部分内容阅读
目的观察培美曲塞一线治疗晚期非小细胞肺癌患者(NSCLC)的疗效并了解其不良反应。方法通过对24例经病理学确诊为非小细胞肺癌患者的分析。了解其疗效,掌握对不良反应的对策。24例患者采用单药培美曲塞治疗。第一天使用培美曲塞600mg/m2进行静脉注射,3周作为一个治疗周期重复治疗,每2个周期评估治疗效果并观察不良反应。结果 24例均为可评价疗效的患者,其中有CR2例,PR12例,SD7例,PD3例。24例病例中出现轻微皮疹2例,6例患者伴有明显疲乏感。部分伴有中性粒细胞数量上的减少、肠道反应、血小板减少、恶心呕吐等症状。处理后都顺利地完成了该项治疗。结论培美曲塞治疗非小细胞肺癌的效果显著,不良反应在能够接受的范围之内。
Objective To observe the efficacy and the adverse effects of pemetrexed in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods 24 cases of pathologically confirmed non-small cell lung cancer patients. Understand its efficacy, master the response to adverse reactions. Twenty-four patients were treated with pemetrexed monotherapy. On the first day, pemetrexed 600 mg / m2 was given intravenously. Three weeks were repeated as one treatment cycle. The therapeutic effect was evaluated every two cycles and adverse reactions were observed. Results All the 24 cases were evaluable curative effect, including CR2 cases, PR12 cases, SD7 cases and PD3 cases. Twenty-four patients had a slight rash in 2 cases, and 6 patients had a clear feeling of fatigue. Part of the decrease in the number of neutrophils, intestinal reactions, thrombocytopenia, nausea and vomiting and other symptoms. After treatment, the treatment was successfully completed. Conclusion Pemetrexed treatment of non-small cell lung cancer has a significant effect, adverse reactions within the acceptable range.